96197-36-3 Usage
Molecular Structure
1-PHENYL-1,4,5,6-TETRAHYDROCYCLOPENTA[C]PYRAZOLE-3-CARBOXYLIC ACID has a complex molecular structure, featuring a tetrahydrocyclopenta[c]pyrazole ring with a phenyl group attached to it.
Chemical Category
1-PHENYL-1,4,5,6-TETRAHYDROCYCLOPENTA[C]PYRAZOLE-3-CARBOXYLIC ACID belongs to the category of carboxylic acids, which are organic compounds containing a carboxyl group (-COOH).
Functional Groups
The specific content in the molecule includes a phenyl group (a ring of six carbon atoms with alternating single and double bonds), a tetrahydrocyclopenta[c]pyrazole ring (a five-membered ring with four carbon atoms and one nitrogen atom, saturated with hydrogen atoms), and a carboxyl group (-COOH).
Potential Applications
Due to its unique structure and properties, 1-PHENYL-1,4,5,6-TETRAHYDROCYCLOPENTA[C]PYRAZOLE-3-CARBOXYLIC ACID may have potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science.
Research and Development
Further research and development are necessary to explore the potential uses of 1-PHENYL-1,4,5,6-TETRAHYDROCYCLOPENTA[C]PYRAZOLE-3-CARBOXYLIC ACID and to determine its safety and efficacy in different applications.
Check Digit Verification of cas no
The CAS Registry Mumber 96197-36-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,6,1,9 and 7 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 96197-36:
(7*9)+(6*6)+(5*1)+(4*9)+(3*7)+(2*3)+(1*6)=173
173 % 10 = 3
So 96197-36-3 is a valid CAS Registry Number.
InChI:InChI=1/C13H12N2O2/c16-13(17)12-10-7-4-8-11(10)15(14-12)9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,16,17)
96197-36-3Relevant academic research and scientific papers
Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation
Yang, Wei,Li, Yingjun,Ai, Yong,Obianom, Obinna N.,Guo, Dong,Yang, Hong,Sakamuru, Srilatha,Xia, Menghang,Shu, Yan,Xue, Fengtian
, p. 11151 - 11164 (2019/12/27)
Dysregulation of the Wnt/β-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.
